Shuhei Imayama

The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-co

O. Nemoto, M. Furue, Hidemi Nakagawa et al. · British Journal of Dermatology · 2015 · 186 citations · Full text

Ceramidase Activity in Bacterial Skin Flora as a Possible Cause of Ceramide Deficiency in Atopic Dermatitis

Yoshinori Ohnishi, Nozomu Okino, Makoto Ito et al. · Clinical and Diagnostic Laboratory Immunology · 1999 · 117 citations · Full text

Purification and Characterization of a Novel Ceramidase fromPseudomonas aeruginosa

Nozomu Okino, Motohiro Tani, Shuhei Imayama et al. · Journal of Biological Chemistry · 1998 · 109 citations · Full text

A hypothetical explanation for the aging of skin. Chronologic alteration of the three-dimensional arrangement of collagen and elastic fibers in connective tissue.

Shuhei Imayama, Irwin M. Braverman · PubMed · 1989 · 108 citations · Full text

Combination of patch test and IgE for dust mite antigens differentiates 130 patients with atopic dermatitis into four groups

Shuhei Imayama, Tamiko Hashizume, Hiroko Miyahara et al. · Journal of the American Academy of Dermatology · 1992 · 101 citations

Allergy, Atopic Dermatitis, Allergy Medicine +10